Novel recombinant strain of mycobacterium smegmatis and use of same
AssigneeClipsbnc Co., Ltd.
InventorsBum-Joon KIM, Dong Ho AHN, Hyein JEONG, Hyejun SEO, Jae Hee KIM
Life of this patent
Estimating the term…
Loading patent…
AssigneeClipsbnc Co., Ltd.
InventorsBum-Joon KIM, Dong Ho AHN, Hyein JEONG, Hyejun SEO, Jae Hee KIM
Estimating the term…
A recombinant Mycobacterium strain co-expressing MIF and IL-7, and a composition containing the strain as an active ingredient are disclosed. The strain and the composition are suitable for preventing or treating cancer. The strain induces a maximized anticancer immune response by stably expressing MIF and IL-7 through a mycobacteria-derived replicable plasmid, such as a pMyong2 shuttle vector. Accordingly, the strain and the composition may be usefully used as an efficient anticancer live vaccine composition that induces multiple cellular and humoral immune responses through single administration of the recombinant strain.
A mycobacteria-derived replicable plasmid comprising:
Dependencies are inferred from the claim text.